In conclusion, our results demonstrate the influence of a constitutive ABCG2 haplotype on the response to imatinib in CP-CML patients and raise the possibility of personalizing imatinib daily doses in this population on the basis of constitutive genotyping. The gene discussed is ABCG2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.